365 related articles for article (PubMed ID: 21684855)
21. The 48-week efficacy of once-daily saquinavir/ritonavir in patients with undetectable viral load after 3 years of antiretroviral therapy.
Cardiello P; Srasuebkul P; Hassink E; Mahanontharit A; Samor T; Ruxrungtham K; Lange J; Cooper D; Phanuphak P
HIV Med; 2005 Mar; 6(2):122-8. PubMed ID: 15807718
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results.
Gatell J; Salmon-Ceron D; Lazzarin A; Van Wijngaerden E; Antunes F; Leen C; Horban A; Wirtz V; Odeshoo L; Van den Dungen M; Gruber C; Ledesma E;
Clin Infect Dis; 2007 Jun; 44(11):1484-92. PubMed ID: 17479947
[TBL] [Abstract][Full Text] [Related]
23. Predictors of virological response to atazanavir in protease inhibitor-experienced patients.
Barrios A; Rendón AL; Gallego O; Martín-Carbonero L; Valer L; Ríos P; Maida I; García-Benayas T; Jiménez-Nácher I; González-Lahoz J; Soriano V
HIV Clin Trials; 2004; 5(4):201-5. PubMed ID: 15472794
[TBL] [Abstract][Full Text] [Related]
24. A randomised comparison of safety and efficacy of nevirapine vs. atazanavir/ritonavir combined with tenofovir/emtricitabine in treatment-naïve patients.
Dejesus E; Mills A; Bhatti L; Conner C; Storfer S
Int J Clin Pract; 2011 Dec; 65(12):1240-9. PubMed ID: 21999631
[TBL] [Abstract][Full Text] [Related]
25. Safety and exposure of once-daily ritonavir-boosted atazanavir in HIV-infected pregnant women.
Conradie F; Zorrilla C; Josipovic D; Botes M; Osiyemi O; Vandeloise E; Eley T; Child M; Bertz R; Hu W; Wirtz V; McGrath D
HIV Med; 2011 Oct; 12(9):570-9. PubMed ID: 21569187
[TBL] [Abstract][Full Text] [Related]
26. Economic and health-related quality-of-life (HRQoL) comparison of lopinavir/ritonavir (LPV/r) and atazanavir plus ritonavir (ATV+RTV) based regimens for antiretroviral therapy (ART)-naïve and -experienced United Kingdom patients in 2011.
Simpson KN; Baran RW; Collomb D; Beck EJ; Van de Steen O; Dietz B
J Med Econ; 2012; 15(4):796-806. PubMed ID: 22563716
[TBL] [Abstract][Full Text] [Related]
27. High incidence of renal stones among HIV-infected patients on ritonavir-boosted atazanavir than in those receiving other protease inhibitor-containing antiretroviral therapy.
Hamada Y; Nishijima T; Watanabe K; Komatsu H; Tsukada K; Teruya K; Gatanaga H; Kikuchi Y; Oka S
Clin Infect Dis; 2012 Nov; 55(9):1262-9. PubMed ID: 22820542
[TBL] [Abstract][Full Text] [Related]
28. Cost effectiveness of lopinavir/ritonavir compared with atazanavir in antiretroviral-naive patients: modelling the combined effects of HIV and heart disease.
Simpson KN; Luo MP; Chumney EC; King MS; Brun S
Clin Drug Investig; 2007; 27(1):67-74. PubMed ID: 17177581
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of ritonavir-boosted and unboosted atazanavir among antiretroviral-naïve patients.
Horberg M; Klein D; Hurley L; Silverberg M; Towner W; Antoniskis D; Kovach D; Mogyoros M; Blake W; Dobrinich R; Dodge W
HIV Clin Trials; 2008; 9(6):367-74. PubMed ID: 19203902
[TBL] [Abstract][Full Text] [Related]
30. Cobicistat versus ritonavir as a pharmacoenhancer of atazanavir plus emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV type 1-infected patients: week 48 results.
Gallant JE; Koenig E; Andrade-Villanueva J; Chetchotisakd P; DeJesus E; Antunes F; Arastéh K; Moyle G; Rizzardini G; Fehr J; Liu Y; Zhong L; Callebaut C; Szwarcberg J; Rhee MS; Cheng AK
J Infect Dis; 2013 Jul; 208(1):32-9. PubMed ID: 23532097
[TBL] [Abstract][Full Text] [Related]
31. A meta-analysis of the efficacy and safety of unboosted atazanavir compared with ritonavir-boosted protease inhibitor maintenance therapy in HIV-infected adults with established virological suppression after induction.
Baril J; Conway B; Giguère P; Ferko N; Hollmann S; Angel JB
HIV Med; 2014 May; 15(5):301-10. PubMed ID: 24314017
[TBL] [Abstract][Full Text] [Related]
32. 96-week efficacy and safety of atazanavir, with and without ritonavir, in a HAART regimen in treatment-naive patients.
Malan DR; Krantz E; David N; Rong Yang ; Mathew M; Iloeje UH; Jun Su ; McGrath D;
J Int Assoc Physicians AIDS Care (Chic); 2010; 9(1):34-42. PubMed ID: 20071596
[TBL] [Abstract][Full Text] [Related]
33. Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppression.
Swindells S; DiRienzo AG; Wilkin T; Fletcher CV; Margolis DM; Thal GD; Godfrey C; Bastow B; Ray MG; Wang H; Coombs RW; McKinnon J; Mellors JW;
JAMA; 2006 Aug; 296(7):806-14. PubMed ID: 16905786
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of boosted and unboosted atazanavir-containing antiretroviral regimens in real life: results from a multicentre cohort study.
Giuntini R; Martinelli C; Ricci E; Vichi F; Gianelli E; Madeddu G; Abeli C; Palvarini L; Penco G; Marconi P; Grosso C; Pellicano G; Bonfanti P; Quirino T
HIV Med; 2010 Jan; 11(1):40-5. PubMed ID: 19686438
[TBL] [Abstract][Full Text] [Related]
35. Virological responses to atazanavir-ritonavir-based regimens: resistance-substitutions score and pharmacokinetic parameters (Reyaphar study).
Pellegrin I; Breilh D; Ragnaud JM; Boucher S; Neau D; Fleury H; Schrive MH; Saux MC; Pellegrin JL; Lazaro E; Vray M
Antivir Ther; 2006; 11(4):421-9. PubMed ID: 16856615
[TBL] [Abstract][Full Text] [Related]
36. Increase in standard cholesterol and large HDL particle subclasses in antiretroviral-naïve patients prescribed efavirenz compared to atazanavir/ritonavir.
Gotti D; Cesana BM; Albini L; Calabresi A; Izzo I; Focà E; Motta D; Bellagamba R; Fezza R; Narciso P; Sighinolfi L; Maggi P; Brianese N; Quiros-Roldan E; Guaraldi G; Torti C
HIV Clin Trials; 2012; 13(5):245-55. PubMed ID: 23134625
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients with virological suppression: 144 week follow-up of the AtLaS pilot study.
Mondi A; Fabbiani M; Ciccarelli N; Colafigli M; D'Avino A; Borghetti A; Gagliardini R; Cauda R; De Luca A; Di Giambenedetto S
J Antimicrob Chemother; 2015; 70(6):1843-9. PubMed ID: 25885326
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of switching to raltegravir plus atazanavir dual therapy in pretreated HIV-1-infected patients over 144 weeks: a cohort study.
Gantner P; Koeppel C; Partisani M; Batard ML; Bernard-Henry C; Cheneau C; De Mautort E; Priester M; Muret P; Sueur C; Fafi-Kremer S; Rey D
Scand J Infect Dis; 2014 Dec; 46(12):838-45. PubMed ID: 25229167
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of efficacy, safety, pharmacokinetics, and adherence in HIV-1-infected, antiretroviral-naïve patients treated with ritonavir-boosted atazanavir plus fixed-dose tenofovir DF/emtricitabine given once daily.
Elion R; Cohen C; Ward D; Ruane P; Ortiz R; Reddy YS; Ebrahimi R; McColl D; Kearney B; Fisher A; Flaherty J;
HIV Clin Trials; 2008; 9(4):213-24. PubMed ID: 18753116
[TBL] [Abstract][Full Text] [Related]
40. Performance of six different ritonavir-boosted protease inhibitor-based regimens in heavily antiretroviral-experienced HIV-infected patients.
de Mendoza C; Valer L; Ribera E; Barreiro P; Martín-Carbonero L; Ramirez G; Soriano V
HIV Clin Trials; 2006; 7(4):163-71. PubMed ID: 17065028
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
